
Immuneering Surges Amid Promising Trial Data! What’s Driving the Surge?
Immuneering Corporation (NASDAQ:IMRX) experienced a remarkable increase in stock price following the announcement of encouraging updates from its ongoing Phase 2a clinical trials for pancreatic cancer treatments. The company is advancing its lead program, IMM-1-104, with plans to broaden the trial to